MEMBER'S AREA
GET IN TOUCH
JOIN US!

New and Emerging Investigators

ISCBH New Investigators Networking Group Logo

In the spirit of fostering the exchange of ideas and peer support for new investigators from around the globe, the ISCBH New Investigator Network was established in late 2020. If you’re interested in knowing more please don’t hesitate to contact us.

Jeanne Franzone, Josephine Tauer and Joanna Tung
ISCBH NI Co-Chairs

Jeanne Franzone

Jeanne Franzone

EMAIL

Josephine Tauer

EMAIL

Joanna Tung

Joanna Tung

EMAIL

About the ISCBH New Investigator Network

OUR GOALS:

  • Identify a group of new investigators in the field of paediatric bone health to facilitate collaboration within that group
  • Offer timely support and a feeling of belonging among the new investigator community
  • Provide dedicated NI sessions to expand knowledge and skills specific to paediatric bone health research

The group organises quarterly webinar meetings and if you are a new investigator we encourage you to get involved!  Membership of the group is totally free of charge.  In the past we’ve organised meetings on topics such as:

  • Grants – How to get your research project funded
  • How to prepare and deliver a good talk
  • Networking for introverts/beginners
  • Boost your career with social media

Emerging Investigator Mentorship

The ISCBH new and emerging investigators group has identified the need for membership opportunities and so are excited to launch our ISCBH Emerging Investigator Program!

Find out more

New Investigator Webinars

The next webinar in the ISCBH NI series will be announced here soon.  In the meantime, if you would like to be added to our NI mailing list please email Kate on events@theiscbh.org

New Investigator Group Webinar

Details about our next webinar will be listed below when confirmed.

Previous New Investigator Webinars

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE